中医益气利水消肿法联合IL-2加顺铂治疗恶性胸腔积液疗效观察

目的 观察中医益气利水消肿法联合白细胞介素-2(IL-2)加顺铂胸腔内注射治疗恶性胸腔积液的疗效和毒副作用.方法 将52例恶性胸腔积液患者随机分为2组,其中治疗组给予胸腔闭式引流后注入IL-2加顺铂治疗,同时联合益气利水消肿中药口服;对照组仅以IL-2加顺铂治疗.2组均连续治疗3周,治疗结束1月后观察2组患者恶性胸腔积...     

芬太尼透皮贴剂治疗中重度癌性疼痛的疗效观察

为进一步观察芬太尼透皮贴剂(多瑞吉)对于中重度癌性疼痛的疗效、不良反应及患者生活质量的改善,对106例伴有中重度疼痛的恶性肿瘤患者,采用芬太尼透皮贴剂进行外敷治疗,记录用药前后疼痛强度、生活质量评分、不良反应以及患者对多瑞吉的偏爱情况。结果疼痛总的缓解率为92.5%(98/106),其中完全缓解47.2%(50/106),明显缓解35.8%(38/106),中度缓解9.4%(10/106)。主要不良反应有头晕、恶心、呕吐、嗜睡和便秘等。对多瑞吉偏好患者占84.9%(90/106)。初步研究结果提示,芬太尼透皮贴剂可有效地控制疼痛,不良反应较小,患者的依从性好。     

Effects of combined Chinese drugs and chemotherapy in treating advanced non-small cell lung cancer

Objective:To evaluate the efficacy and side effects of combined Chinese drugs and chemotherapy in treating advanced non-small cell lung cancer(NSCLC).Methods:Sixty-three patients with stageⅢB andⅣNSCLC hospitalized from October 2001 to October 2008 were enrolled and assigned to two groups using a randomizing digital table,with 33 patients in the treatment group and 30 in the control group. They were all treated with the Navelbine and Cisplatin(NP) chemotherapy,but to the treatment group the Chinese drugs...     

中医与西医治疗晚期非小细胞肺癌病人远期生存率的临床研究

Objective： To investigate the prognostic influence on long-term overall survival （OS） from treatment with Chinese medicine （CM） and chemotherapy or targeted therapy in advanced non-small-cell lung cancer （NSCLC） patients. Methods： The clinical data of 206 advanced NSCLC patients who were treated with CM and Western medicine in Beijing Cancer Hospital from April 1999 to July 2013 were retrospectively analyzed. Long-term survivors were defined as OS ≥ 3 years after treatment with CM and chemotherapy. Twenty-eight patients had OS ≥ 3 years, 178 had OS 〈 3 years, and all clinical data were statistically analyzed with the Cox model. Variables were gender, age, smoking status, performance status （PS） score, pathological type, clinical stage, first-line chemotherapy, targeted therapy, and use of CM. Univariate survival analysis was performed using the Kaplan-Meier method and log-rank sequential inspection. Multivariate survival analysis was used to analyze the meaningful factors of univariate survival analysis with the Cox model. Results： The survival rate of patients with OS ≥ 3 years was 13.6% （28/206）. Cox multivariate regression analysis showed that PS score, clinical stage, disease control rate to first-line chemotherapy, and use of CM were independent factors of long- term OS （all P〈0.05）. However, gender, age, smoking, and use of epidermal growth factor receptor tyrosine- kinase inhibitor were not significant （P〉0.05）. Conclusion： PS score, clinical stage, disease control rate to first- line chemotherapy, and use of CM are probably independent prognostic factors for long-term OS in patients with advanced NSCLC.     

直肠癌合并皮肌炎1例

患者女性，６７岁，因面部、四肢皮疹２月余，近端肌无力１个月，便血半个月。于１９９７年６月就诊于北医大第一临床医院皮肤科，查体：两颊、前额、胸背部、四肢伸侧出现暗红色斑。丘疹，指间及掌指关节处可见Ｇｏｔｔｒｏｎ征，近端肌力下降，肌电图示肌损害，实验室指标异常：ＣＰＫ ３ ３００ＩＵ／Ｌ。ＬＤＨ５６３１Ｕ／Ｌ、ＧＯＴ１７８ＩＵ／Ｌ、ＧＰＴ １６３ＩＵ、ＡＮＡ：阳性１：１６０斑点型，胸片、心电图、腹部Ｂ超未见异常。确诊为皮肌炎。遂给予强的松６０ｍｇ／ｄ，治疗１０天后面部、四肢红斑、实验室指标明显好转，但…     

20例原发性肝癌死亡原因分析

原发性肝癌位居恶性肿瘤的第3位,我科1995年12月～2001年1月共收治的原发性肝癌59例,其中20例死亡,现对其死亡原因分析如下。     

放化疗性口腔黏膜炎的中西医治疗

口腔黏膜炎是临床常见的一种口腔疾病，发病率很高，且易复发。其发病机理尚不十分清楚。引起口腔黏膜炎的原因很多，而恶性肿瘤患者在接受放疗、化疗的同时，极易并发口腔黏膜炎，成为口腔黏膜炎的常见原因之一。对于放化疗所引起的口腔黏膜炎，又称之为放化疗性口腔黏膜炎。现将放化疗性口腔黏膜炎的中西医疗法综述如下。     

欧耐特治疗恶性胸腹腔积液的疗效观察

目的;观察欧耐特（重组人白细胞介素－２）胸腹腔内注射治疗恶性胸腹水的疗效和副作用。方法：自１９９６年３月至１９９８年５月,对２４例恶性胸腹水患者（其中１１例为恶性胸腔积液,１３你为恶性腹腔积液）,采用北京中华生物技术有限公司研制的欧耐特９ｒｈＩｌ－２）胸腹腔内注射法进行疗效观察。尽量抽尽胸腹水后,胸腔内每次注入欧耐生气勃勃００万Ｕ,腹腔内每次注入２００～４００万Ｕ,注射１～２次／Ｗ,连用２～３周,     

88例晚期肿瘤住院患者营养风险评价

目的探讨晚期肿瘤住院患者的营养风险发生情况。方法采用营养风险筛查量表(NRS2002)对88例晚期肿瘤住院患者进行营养风险筛查,采用美国东部肿瘤协作组(ECOG)分级评分评价患者体力状态,记录患者肿瘤部位、症状、中医证型及住院日,分析营养风险与ECOG分级、患者住院日的关系。结果 88例晚期肿瘤住院患者中有营养风险的患者(即NRS2002评分≥3分)42例占47.7%。消化系统肿瘤患者营养风险发生率56.8%(25/44),其中食管癌100%(5/5)、胰腺癌100%(4/4)、胃癌66.7%(4/6)、壶腹癌66.7%(2/3)。ECOG分级3~4级者11例,其中有营养风险者占81.8%显著高于无营养风险者的18.2%(χ2=6.099,P0.05)。有营养风险患者平均住院日(29.2±19.1)天,显著多于无营养风险患者的(20.5±15.1)天(P0.05)。有营养风险的晚期肿瘤住院患者最常见的消化道症状是厌食(64.3%)、恶心呕吐(21.4%),最常见的中医证型为脾气虚(35.7%)、湿热蕴脾(21.4%)和寒湿困脾证(19.0%)。结论晚期肿瘤住院患者营养风险发生率较高,并且ECOG分级3~4级患者营养风险发生率高,有营养风险患者住院时间相对更长。